1.	Phase III Diagnostic Study of Blue Light Fluorescent Cystoscopy With Reconstituted Hexyl 5-Aminolevulinate (Hexvix®) Versus White Light Cystoscopy for the Detection of Carcinoma in Situ in Patients With Bladder Cancer Phase: Phase III Type: Diagnostic Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0201058, POA-B30/01, NCT00052637
2.	Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy Phase: Phase III Type: Diagnostic Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PC B305/02, NCT00233402
3.	Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study Phase: Phase II, Phase I Type: Diagnostic Status: Completed Age: 18 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: PCCO101/05, NCT00285701
4.	A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PC CE101/06, NCT00369018
5.	Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PC CE203/10, NCT01256424
6.	Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer Phase: No phase specified Type: Diagnostic Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: GEH-HEX-2007-01, NCT00634621